<DOC>
	<DOCNO>NCT02867618</DOCNO>
	<brief_summary>This open label , phase I/II , dose-escalation study initial phase I follow phase II . The primary objective phase I determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) combination TGR-1202 carfilzomib participant relapse refractory ( R/R ) non-Hodgkin lymphoma ( NHL ) Hodgkin lymphoma ( HL ) . The safety toxicity combination evaluate throughout entire study . If combination TGR-1202 carfilzomib find feasible MTD establish , phase II part study initiate . Phase II consist 2-stage design combination TGR-1202 carfilzomib participant R/R NHL .</brief_summary>
	<brief_title>Carfilzomib TGR-1202 Treatment R/R Lymphoma</brief_title>
	<detailed_description>Dysregulated c-Myc associate resistance chemotherapy poor survival aggressive lymphoma . Novel strategy target biology could markedly improve outcome participant . To date drug directly target Myc approve cancer treatment . Recent result Deng et al . ( Blood . 2017 Jan 5 . PMID : 27784673 ) describe highly synergistic regimen discover preclinical model , combine TGR-1202 , investigational drug inhibits PI3K delta , carfilzomib , drug approve FDA multiple myeloma . Importantly , combination TGR-1202 carfilzomib act potently silence translation c-Myc induce apoptosis many cell line primary lymphoma cell represent broad histological subtypes lymphoma . These result suggest TGR-1202 carfilzomib may highly effective relapse refractory lymphoma c-Myc play key pathological role .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Phase I : Patients must histologically confirm R/R NHL HL ( define WHO criterion ) . Patients chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) eligible . Phase II : Patients must histologically confirm R/R NHL ( define WHO criterion ) . Must receive front line chemotherapy . No upper limit number prior therapy Evaluable Disease Phase I , measurable disease define Section 11 Phase II . Age &gt; 18 year . ECOG performance status &lt; 2 Patients must adequate organ marrow function define Section 3 . Adequate Contraception Ability understand willingness sign write informed consent document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>